Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).

CONCLUSION: Neoadjuvant aromatase inhibitor therapy is an acceptable strategy in selected postmenopausal patients with ER-rich and HER2-negative early breast cancer with ductal histology and should be considered when chemotherapy either isn't indicated or feasible. PMID: 29168427 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29168427?dopt=Abstract

Source: Acta Oncologica - November 23, 2017 Category: Cancer & Oncology Authors: Skriver SK, Laenkholm AV, Rasmussen BB, Handler J, Grundtmann B, Tvedskov TF, Christiansen P, Knoop AS, Jensen MB, Ejlertsen B Tags: Acta Oncol Source Type: research